Among the FDA‐approved urine‐based biomarker assays for bladder cancer detection and surveillance, including the Bladder Tumor Antigen (BTA) test, Nuclear Matrix Protein 22 (NMP22) test, and UroVysion test, the reported diagnostic performance remains suboptimal, with an overall sensitivity of 57%–82% and a negative predictive value (NPV) of 21%–48% [9, 10]. The gene discussed is NUMA1; the disease is urinary bladder cancer.